Cargando…

SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol

INTRODUCTION: The COmmunity Cohort Study aims to determine, after natural exposure to SARS-CoV-2 or anti-SARS-CoV-2 vaccines deployed in Chile to prevent COVID-19 in the context of the current pandemic, the strength and duration of detectable neutralising antibodies in adult ambulatory primary care...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachelet, Vivienne C, Silva-Ayarza, Ignacio, Lizana, Francisca J, Gomolán, Patricio, Silva-Villalobos, Diego, Navarrete, María S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121110/
https://www.ncbi.nlm.nih.gov/pubmed/35589344
http://dx.doi.org/10.1136/bmjopen-2022-061345
_version_ 1784711086171226112
author Bachelet, Vivienne C
Silva-Ayarza, Ignacio
Lizana, Francisca J
Gomolán, Patricio
Silva-Villalobos, Diego
Navarrete, María S
author_facet Bachelet, Vivienne C
Silva-Ayarza, Ignacio
Lizana, Francisca J
Gomolán, Patricio
Silva-Villalobos, Diego
Navarrete, María S
author_sort Bachelet, Vivienne C
collection PubMed
description INTRODUCTION: The COmmunity Cohort Study aims to determine, after natural exposure to SARS-CoV-2 or anti-SARS-CoV-2 vaccines deployed in Chile to prevent COVID-19 in the context of the current pandemic, the strength and duration of detectable neutralising antibodies in adult ambulatory primary care patients with cardiovascular risk factors. METHODS AND ANALYSIS: We will set up a community-based longitudinal, prospective cohort study. The study will be conducted in two public outpatient clinics located in the southern district of Santiago, Chile. We expect to begin recruitment in the second quarter of 2022. Each patient will be followed up for at least 1 year after inclusion in the cohort. The eligible population will be adult patients registered in the Cardiovascular Health Programme. Exposure in this study is defined as any event where participants have contact with SARS-CoV-2 antigens from natural exposure or vaccination. The primary outcomes are seroconversion and strength and duration of the neutralising IgG antibodies to SARS-CoV-2. Secondary outcomes are any COVID-19-related event or intercurrent morbidities or death. Data will be collected by extracting serial blood samples and administering a questionnaire at the first face-to-face contact and monthly follow-up time points. The sample size estimated for this study is 1060. We will characterise the cohort, determine the seroprevalence rate of neutralising antibodies at baseline and determine the rates of antibody decline using a longitudinal mixed-effects model. ETHICS AND DISSEMINATION: The Scientific Ethics Committee of the South Metropolitan Health Care Service approved the study protocol (Memorandum No 191/2021). We will present the results in two peer-reviewed publications and national and international professional and academic meetings. We will organise seminars with relevant stakeholders and hold town hall meetings with the local community. We will set up a COmmunity Cohort Study website at www.communitystudy.cl to disseminate the study purpose, research team and milestones.
format Online
Article
Text
id pubmed-9121110
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91211102022-05-20 SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol Bachelet, Vivienne C Silva-Ayarza, Ignacio Lizana, Francisca J Gomolán, Patricio Silva-Villalobos, Diego Navarrete, María S BMJ Open Epidemiology INTRODUCTION: The COmmunity Cohort Study aims to determine, after natural exposure to SARS-CoV-2 or anti-SARS-CoV-2 vaccines deployed in Chile to prevent COVID-19 in the context of the current pandemic, the strength and duration of detectable neutralising antibodies in adult ambulatory primary care patients with cardiovascular risk factors. METHODS AND ANALYSIS: We will set up a community-based longitudinal, prospective cohort study. The study will be conducted in two public outpatient clinics located in the southern district of Santiago, Chile. We expect to begin recruitment in the second quarter of 2022. Each patient will be followed up for at least 1 year after inclusion in the cohort. The eligible population will be adult patients registered in the Cardiovascular Health Programme. Exposure in this study is defined as any event where participants have contact with SARS-CoV-2 antigens from natural exposure or vaccination. The primary outcomes are seroconversion and strength and duration of the neutralising IgG antibodies to SARS-CoV-2. Secondary outcomes are any COVID-19-related event or intercurrent morbidities or death. Data will be collected by extracting serial blood samples and administering a questionnaire at the first face-to-face contact and monthly follow-up time points. The sample size estimated for this study is 1060. We will characterise the cohort, determine the seroprevalence rate of neutralising antibodies at baseline and determine the rates of antibody decline using a longitudinal mixed-effects model. ETHICS AND DISSEMINATION: The Scientific Ethics Committee of the South Metropolitan Health Care Service approved the study protocol (Memorandum No 191/2021). We will present the results in two peer-reviewed publications and national and international professional and academic meetings. We will organise seminars with relevant stakeholders and hold town hall meetings with the local community. We will set up a COmmunity Cohort Study website at www.communitystudy.cl to disseminate the study purpose, research team and milestones. BMJ Publishing Group 2022-05-18 /pmc/articles/PMC9121110/ /pubmed/35589344 http://dx.doi.org/10.1136/bmjopen-2022-061345 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Bachelet, Vivienne C
Silva-Ayarza, Ignacio
Lizana, Francisca J
Gomolán, Patricio
Silva-Villalobos, Diego
Navarrete, María S
SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol
title SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol
title_full SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol
title_fullStr SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol
title_full_unstemmed SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol
title_short SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol
title_sort sars-cov-2 humoral immune response in patients with cardiovascular risk factors: the community cohort study protocol
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121110/
https://www.ncbi.nlm.nih.gov/pubmed/35589344
http://dx.doi.org/10.1136/bmjopen-2022-061345
work_keys_str_mv AT bacheletviviennec sarscov2humoralimmuneresponseinpatientswithcardiovascularriskfactorsthecommunitycohortstudyprotocol
AT silvaayarzaignacio sarscov2humoralimmuneresponseinpatientswithcardiovascularriskfactorsthecommunitycohortstudyprotocol
AT lizanafranciscaj sarscov2humoralimmuneresponseinpatientswithcardiovascularriskfactorsthecommunitycohortstudyprotocol
AT gomolanpatricio sarscov2humoralimmuneresponseinpatientswithcardiovascularriskfactorsthecommunitycohortstudyprotocol
AT silvavillalobosdiego sarscov2humoralimmuneresponseinpatientswithcardiovascularriskfactorsthecommunitycohortstudyprotocol
AT navarretemarias sarscov2humoralimmuneresponseinpatientswithcardiovascularriskfactorsthecommunitycohortstudyprotocol